TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07284433: Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

Sponsor: AvenCell Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 178 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$4,751,670

Rescue Site Savings

+$3,141,600

Unlock Full NCT07284433 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07284433 Rescue Dossier →